Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-specific Antigen Screening

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2010 Apr 22

PMID 20406957

Citations 12

Authors

Caroline J Savage

Hans Lilja

Angel M Cronin

David Ulmert

Andrew J Vickers

Affiliations

Soon will be listed here.

Abstract

Background: Lead time, the estimated time by which screening advances the date of diagnosis, is used to calculate the risk of overdiagnosis. We sought to describe empirically the distribution of lead times between an elevated prostate-specific antigen (PSA) and subsequent prostate cancer diagnosis.

Methods: We linked the Swedish cancer registry to two independent cohorts: 60-year-olds sampled in 1981-1982 and 51- to 56-year-olds sampled in 1982-1985. We used univariate kernel density estimation to characterize the lead time distribution. Linear regression was used to model the lead time as a function of baseline PSA and logistic regression was used to test for an association between lead time and either stage or grade at diagnosis.

Results: Of 1,167 older men, 132 were diagnosed with prostate cancer, of which 57 had PSA>or=3 ng/mL at baseline; 495 of 4,260 younger men were diagnosed with prostate cancer, of which 116 had PSA>or=3 ng/mL at baseline. The median lead time was slightly longer in the younger men (12.8 versus 11.8 years). In both cohorts, wide variation in lead times followed an approximately normal distribution. Longer lead times were significantly associated with a lower risk of high-grade disease in older and younger men [odds ratio, 0.82 (P=0.023) and 0.77 (P<0.001)].

Conclusion: Our findings suggest that early changes in the natural history of the disease are associated with high-grade cancer at diagnosis.

Impact: The distinct differences between the observed distribution of lead times and those used in modeling studies illustrate the need to model overdiagnosis rates using empirical data.

Citing Articles

F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis.

Barnett C, Davenport M, Montgomery J, Kunju L, Denton B, Piert M J Nucl Med. 2019; 60(12):1705-1712.

PMID: 31350321 PMC: 6894371. DOI: 10.2967/jnumed.119.225771.

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.

Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H Eur Urol. 2017; 73(6):961-967.

PMID: 29066048 PMC: 5911245. DOI: 10.1016/j.eururo.2017.10.004.

Management of localized prostate cancer: the pendulum swings (back to the middle).

Vuong W, Sartor O, Pal S Asian J Androl. 2014; 16(4):570-1.

PMID: 24875822 PMC: 4104085. DOI: 10.4103/1008-682X.131072.

Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.

Vertosick E, Poon B, Vickers A J Urol. 2014; 192(3):724-8.

PMID: 24641912 PMC: 4143426. DOI: 10.1016/j.juro.2014.03.032.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers A, Sjoberg D, Ulmert D, Vertosick E, Roobol M, Thompson I BMC Med. 2014; 12:26.

PMID: 24512643 PMC: 3922189. DOI: 10.1186/1741-7015-12-26.

References

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

Ulmert D, Serio A, OBrien M, Becker C, Eastham J, Scardino P . Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened.... J Clin Oncol. 2008; 26(6):835-41. DOI: 10.1200/JCO.2007.13.1490. View

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Davidov O, Zelen M . Overdiagnosis in early detection programs. Biostatistics. 2004; 5(4):603-13. DOI: 10.1093/biostatistics/kxh012. View

Schroder F, van den Bergh R, Wolters T, van Leeuwen P, Bangma C, van der Kwast T . Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol. 2009; 57(2):256-66. DOI: 10.1016/j.eururo.2009.10.031. View

Pashayan N, Duffy S, Pharoah P, Greenberg D, Donovan J, Martin R . Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer. 2009; 100(7):1198-204. PMC: 2670005. DOI: 10.1038/sj.bjc.6604973. View

Vickers A, Lilja H . Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol. 2009; 6(6):301-3. PMC: 2862723. DOI: 10.1038/nrurol.2009.95. View

Draisma G, de Koning H . MISCAN: estimating lead-time and over-detection by simulation. BJU Int. 2004; 92 Suppl 2:106-11. DOI: 10.1111/j.1464-410x.2003.4409x.x. View

10.

Pearson J, Carter H . Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol. 1994; 152(5 Pt 2):1743-8. DOI: 10.1016/s0022-5347(17)32375-3. View

11.

Etzioni R, Legler J, Feuer E, Merrill R, Cronin K, Hankey B . Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999; 91(12):1033-9. DOI: 10.1093/jnci/91.12.1033. View

12.

Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U . Lead time associated with screening for prostate cancer. Int J Cancer. 2003; 108(1):122-9. DOI: 10.1002/ijc.11554. View

13.

Gann P, Hennekens C, Stampfer M . A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273(4):289-94. View

14.

Draisma G, Boer R, Otto S, van der Cruijsen I, Damhuis R, Schroder F . Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95(12):868-78. DOI: 10.1093/jnci/95.12.868. View

15.

Barry M . Screening for prostate cancer--the controversy that refuses to die. N Engl J Med. 2009; 360(13):1351-4. DOI: 10.1056/NEJMe0901166. View

16.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R . Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101(6):374-83. PMC: 2720697. DOI: 10.1093/jnci/djp001. View

17.

Telesca D, Etzioni R, Gulati R . Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2007; 64(1):10-9. DOI: 10.1111/j.1541-0420.2007.00825.x. View

18.

Carter H, Landis P, Metter E, Fleisher L, Pearson J . Prostate-specific antigen testing of older men. J Natl Cancer Inst. 1999; 91(20):1733-7. PMC: 3474977. DOI: 10.1093/jnci/91.20.1733. View

19.

Kafadar K, Prorok P . Computational methods in medical decision making: to screen or not to screen?. Stat Med. 2005; 24(4):569-81. DOI: 10.1002/sim.2037. View

20.

Breslow N, Chan C, Dhom G, Drury R, FRANKS L, Gellei B . Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977; 20(5):680-8. DOI: 10.1002/ijc.2910200506. View